This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Updated Safety Recommendation - Abrocitinib should only be used if no suitable treatment alternatives are available in patients: 65 years of age and older, patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), patients with malignancy risk factors (e.g. current malignancy or a history of malignancy). (Cibinqo Summary of Product Characteristics)
This pivotal Phase III clinical trial evaluated the efficacy and safety of Cibinqo in combination with medicated topical therapy versus placebo in 287 adolescent patients age 12–17 years with moderate-to-severe AD. Patients used non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids and other medicated topicals per protocol guidance to treat active lesions during the study2
Adapted from Eichenfield L, et al. JAMA Dermatol 2021;157(10):1165-1173.
*Patients not eligible for JADE EXTEND entered the 4-week off-treatment follow-up period.
¥Two patients randomly assigned to receive abrocitinib, 200mg, were not treated and were not included in the analysis sets.2
The recommended starting dose for adolescents (12-17 years old) is 100 mg1
Change from baseline in PSAAD at Week 12
Cibinqo | ||||
---|---|---|---|---|
Placebo (N=96) | 100 mg (N=95) | 200 mg (N=94) |
All (N=285) |
|
Age, median (IQR), y | 14.0 (13.5–16.5) | 16.0 (14.0–17.0) | 15.0 (13.0–16.0) | 15.0 (13.0–17.0) |
Age group, y • 12–17* • ≥18† |
• 95 (99.0) • 1 (1.0) |
• 95 (100.0) • 0 |
• 94 (100.0) • 0 |
• 284 (99.6) • 1 (0.4) |
Female | 52 (54.2) | 50 (52.6) | 38 (40.4) | 140 (49.1) |
Male | 44 (45.8) | 45 (47.4) | 56 (59.6) | 145 (50.9) |
Race, n (%) • White • Asian • Black or African American • Multiracial • Other‡ • Not reported |
• 56 (58.3) • 32 (33.3) • 3 (3.1) • 1 (1.0) • 2 (2.0) • 2 (2.1) |
• 52 (54.7) • 31 (32.6) • 9 (9.5) • 0 • 3 (3.2) • 0 |
• 52 (55.3) • 31 (33.0) • 5 (5.3) • 1 (1.1) • 5 (5.4) • 0 |
• 160 (56.1) • 94 (33.0) • 17 (6.0) • 2 (0.7) • 10 (3.5) • 2 (0.7) |
Ethnicity, n (%) • Not Hispanic or Latino • Hispanic or Latino • Not reported |
• 65 (67.7) • 25 (26.0) • 6 (6.3) |
• 63 (66.3) • 26 (27.4) • 6 (6.3) |
• 69 (73.4) • 25 (26.6) • 0 |
•197 (69.1) • 76 (26.7) • 12 (4.2) |
Disease duration, mean (SD), years | 10.5 (4.8) | 9.8 (5.4) | 9.7 (5.3) | 10.0 (5.2) |
Prior medication for atopic dermatitis§ • Any prior medication • Topical agents alone¶ • Systemic ± topical agents# • Dupilumab |
• 95 (99.0) • 71 (74.0) • 24 (25.0) • 1 (1.0) |
• 95 (100.0) • 68 (71.6) • 27 (28.4) • 1 (1.1) |
• 92 (97.9) • 70 (74.5) • 22 (23.4) • 1 (1.1) |
• 282 (98.9) • 209 (73.3) • 73 (25.6) • 3 (1.1) |
IGA score • 3 • 4 |
• 57 (59.4) • 39 (40.6) |
• 57 (60.0) • 38 (40.0) |
• 61 (64.9) • 33 (35.1) |
• 175 (61.4) • 110 (38.6) |
EASI score, mean (SD) | 29.2 (12.7) | 31.0 (12.8) | 29.5 (12.2) | 29.9 (12.5) |
BSA affected, mean (SD), % | 45.8 (22.4) | 51.2 (21.7) | 48.7 (21.7) | 48.6 (22.0) |
PP-NRS total score | 7.2 (1.7) | 7.0 (1.8) | 6.8 (2.0) | 7.0 (1.8) |
PSAAD • No. of patients • Total score, mean (SD) |
• 95 • 5.0 (2.4) |
• 95 • 4.9 (2.1) |
• 93 • 4.8 (2.3) |
• 283 • 4.9 (2.3) |
SCORAD • No. of patients • Total score, mean (SD) |
• 96 • 68.5 (13.4) |
• 95 • 67.6 (13.5) |
• 93 • 66.2 (13.3) |
• 284 • 67.5 (13.4) |
SCORAD Sleep Loss VAS • No. of patients • Total score, mean (SD) |
• 96 • 5.7 (2.9) |
• 95 • 5.3 (2.9) |
• 93 • 5.6 (2.9) |
• 284 • 5.5 (2.9) |
CDLQI • No. of patients • Total score, mean (SD) |
• 96 • 14.0 (6.7) |
• 95 • 14.3 (6.1) |
• 94 • 13.6 (7.0) |
• 285 • 14.0 (6.6) |
POEM • No. of patients • Total score, mean (SD) |
• 95 • 19.8 (5.9) |
• 95 • 19.5 (6.4) |
• 94 • 19.2 (6.2) |
• 284 • 19.5 (6.2) |
*One patient in the Cibinqo 200 mg group was age 11 years at the time of consent to participate in the study, which was a protocol deviation.
†One patient in the placebo group was enrolled at age 18 years, which was a protocol deviation.
‡Includes patients who identified as American Indian or Alaskan native and native Hawaiian or Pacific Islander.
§Patients were counted once for each main category (i.e., topical agents or systemic agents) in an exclusive manner.
¶Patients used non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids and other medicated topicals as per protocol guidance to treat active lesions during the study.
#Systemic agents included corticosteroids, cyclosporin, nonbiologic agents, and biologic agents.
In 12 weeks, 68.5% of adolescent patients treated with Cibinqo 100 mg achieved EASI-75 vs 41.5% with placebo (P<0.05).1–3
Adapted from Eichenfield L, et al. JAMA Dermatol 2021;157(10):1165-1173.
The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.1
In 12 weeks, 41.6% of adolescent patients treated with Cibinqo 100 mg achieved IGA 0/1 vs 24.5% with placebo (P<0.05).1–3
After 2 weeks, 27.2% of adolescent patients treated with Cibinqo 100 mg achieved PP-NRS4 vs 12.6% with placebo (P=0.0119).1,2
Adapted from Eichenfield L, et al. JAMA Dermatol 2021;157(10):1165-1173.
The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.1
Access safety information for abrocitinib
References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.
Learn more about flexible dosing in patients on Cibinqo.
AD=atopic dermatitis; OD= once daily; BSA=body surface area; CDLQI=Children's Dermatology Life Quality Index; CI=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; IQR=interquartile range; JAK=Janus kinase; NS=not significant; PDE4=Type 4 cyclic nucleotide phosphodiesterase; POEM=Patient-Oriented Eczema Measure; PP-NRS=Peak Pruritus Numerical Rating Scale; PSAAD=Pruritus and Symptoms Assessment for Atopic Dermatitis; SCORAD=SCORing Atopic Dermatitis; SD=standard deviation; VAS=Visual Analog Scale.
References:
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc/product/12874/rmms. Patients treated with Cibinqo should be given the Patient Card.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.